این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Journal of Pharmaceutical Care، جلد ۸، شماره ۴، صفحات ۱۷۰-۱۷۵
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Nilotinib and Imatinib Utilization in Iran over 14 years
چکیده انگلیسی مقاله Background: Tyrosine Kinase Inhibitors (TKIs) are drugs of choice for Chronic Myeloid Leukemia (CML) treatment. CML healthcare costs greatly exceed of other haematological malignancies treatment mostly due to TKIs. There are several generic and brand preparations of imatinib and nilotinib, the only available TKIs, in Iran with different prices and varied insurance coverage. We have studied TKIs utilization and also investigate the effect of different insurance coverage on TKIs utilization in Iran. Methods: This was drug utilization study about Imatinib and Nilotinib over 14 years. It was conductedin two phases; data extraction from pharmaceutical wholesale data (2003-2017) for utilization trend assessment and registered data of prescriptions from Sizdah-Aban Pharmacy (2011-2014) for utilization trend and insurance coverage assessment such as; prescriptions frequency, number of TKIs, insurance companies and their cost coverage in each prescription. Results: Imatinib consumption increased signifcantly from 2003 to 2013. This trend stoppedafterward. Nilotinib consumption had ascending trend. The trend line of years 2014 to 2017was steeper and statistically signifcant (β=0.0014, p-value=0.02). The amount of nilotinib costcoverage by insurance companies increased signifcantly from 2011 to 2014 (p-value=0.04). The coverage of imatinib costs by insurance companies changed slightly during the study period that was not statistically signifcant. Frequency of prescriptions with full cost coverage doubled for nilotinib, while did not change remarkably for imatinib, from 2011 to 2014. Mean (SD) of imatinib and nilotinib counts per prescription was signifcantly higher in prescriptions for which 100% of the cost was covered. Conclusion: We found increasing trend in nilotinib utilization and observed some effects fromnilotinib cost coverage by insurance on its consumption. This study made a clear picture for policy makers to monitor imatinib and nilotinib use appropriateness and design the proper cost-effective studies to make evidence-based decisions
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Ava Mansouri
Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran


| Kimia Hirbod
Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran


| Maryam Taghizadeh-Ghehi
Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran


| Aarefeh Jafarzadeh Kohneloo
Department of Epidemiology and Biostatistics, Faculty of Health, Tehran University of Medical Sciences, Tehran, Iran


| Mohammad Solduzian
Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran


| Molouk Hadjibabaie
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran AND Research Center for Rational Use of Drugs Tehran University of Medical Sciences, Tehran, Iran
نشانی اینترنتی https://jpc.tums.ac.ir/index.php/jpc/article/view/378
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات